Acadia Pharmaceuticals Inc. posted $308 million in total revenue for the second quarter, a 16% increase year-over-year, exceeding consensus by delivering an EPS of $0.18. This performance, along with an updated full-year revenue guidance raised to between $1.24 and $1.30 billion, signals significant growth prospects for investors.
Key Highlights
- This increase translates to a strong adjusted revenue growth of 17% year-over-year.
- Acadia's GAAP net sales for DAYBUE reached $125 million for the quarter, marking a strong 30% jump from $96 million in Q2 2025.
- The revision indicates solid future revenue streams while demonstrating management's growing confidence in its product lines.
This increase translates to a strong adjusted revenue growth of 17% year-over-year. Acadia's earnings per share (EPS) came in at $0.18, significantly outperforming the consensus estimate of $0.06. Strong performance from both its primary products, NUPLAZID and DAYBUE, has bolstered investor confidence, as indicated by its shares increasing 5.4% over the past month.
Market dynamics also show a supportive environment, with peers like TVTX up 14%.
Revenue Breakdown
Acadia's GAAP net sales for DAYBUE reached $125 million for the quarter, marking a strong 30% jump from $96 million in Q2 2025. Meanwhile, NUPLAZID generated net sales of $183 million, a 9% increase year-over-year. Combined, these figures illustrate effective commercial strategies and heightened demand for Acadia's offerings.
The strong results reflect the company's commitment to expanding its market presence, particularly for DAYBUE, which has seen significant uptake driven by ongoing marketing efforts. This traction is important as Acadia sets its sights on long-term revenue targets.
Revised Financial Guidance
The revision indicates solid future revenue streams while demonstrating management's growing confidence in its product lines. This updated guidance is particularly enticing to investors looking for growth potential in a competitive market.
Upcoming Catalysts
The results from this study could lead to critical advancements in the Alzheimer's treatment environment and enhance Acadia's market position. The company has received FDA Fast Track designation for remlifanserin, highlighting its potential to address unmet medical needs. Investors should closely monitor these developments as they could significantly impact stock performance and company valuation moving forward.
Peers Moving on This News
- Scholar Rock Holding Corp (SRRK) up 1.1%
- Travere Therapeutics Inc (TVTX) up 14.0%
- Dyne Therapeutics, Inc (DYN) little changed
Analysis based on the Form 8-K filed 4 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.


_11_18_2026_14_40_45_405856.jpg)



Please wait processing your request...